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The potential for the use of Clostridial neuro-
toxins as bioweapons makes the development
of small-molecule inhibitors of these deadly
toxins a top priority. Recently, screening of a
random hydroxamate library identified a small-
molecule inhibitor of C. botulinum Neurotoxin
Serotype A Light Chain (BoNT/A-LC), 4-chloro-
cinnamic hydroxamate, a derivative of which
has been shown to have in vivo efficacy in
mice and no toxicity. We describe the X-ray
crystal structures of BoNT/A-LC in complexes
with two potent small-molecule inhibitors. The
structures of the enzymewith 4-chlorocinnamic
hydroxamate or 2,4-dichlorocinnamic hydroxa-
mate bound are compared to the structure of
the enzyme complexed with L-arginine hydrox-
amate, an inhibitor with modest affinity. Taken
together, this suite of structures provides
surprising insights into the BoNT/A-LC active
site, including unexpected conformational flex-
ibility at the S10 site that changes the electro-
static environment of the binding pocket. Infor-
mation gained from these structures will inform
the design and optimization of more effective
small-molecule inhibitors of BoNT/A-LC.
INTRODUCTION
The neurotoxins produced by Clostridium botulinum
(BoNTs), the most potent toxins known, are the causative
agents of botulism, a lethal form of food poisoning. How-
ever, the importance of BoNTs has grown far beyond the
estimated 250 annual cases of botulism. In recent years,
BoNTs have become valuable treatments for a diverse ar-
ray of conditions as severe as chronic pain, migraines, and
cancer and as minor as tennis elbow and facial wrinkles.
Perhaps most important, however, is the threat posedChemistry & Biology 14,by those willing to use botulinum neurotoxins as weapons
of bioterrorism [1–3]. The deliberate release of botulinum
toxin into the nation’s food or water supply could poten-
tially result in hundreds of thousands of casualties [4]. A
botulism outbreak of this magnitude would render the cur-
rent treatments of BoNT intoxication inadequate.
Presently, treatment relies on antibodies capable of
binding to and inhibiting BoNT endocytosis by neuronal
cells. This requires knowledge of intoxication before the
toxin is able to enter cells and cause symptoms, in most
cases less than 24 hr. Thus, there is an urgent need for
small-molecule inhibitors of botulinum toxins that target
the toxin after it enters the cell.
Clostridium botulinum neurotoxin has been classified
into seven antigenically unique serotypes (A–G), all of
which are synthesized as a single protein of 150 kDa
(1295 residues) with three functional domains. After trans-
lation, the holotoxin is proteolyzed to yield the mature mol-
ecule, where the two polypeptide chains remain linked by
a disulfide bond. The 50 kDa light chain (LC; residues 1–
448 of the holotoxin) is a Zn(II)-dependent endoprotease
belonging to the thermolysin family of metalloproteases.
The 100 kDa heavy chain (HC) contains an N-terminal
translocation domain (residues 449–872) and a C-terminal
receptor-binding domain (residues 873–1295) [5–7].
BoNT intoxication has been described as a four-step
process [8–11]. First, the toxin is ingested and enters the
bloodstream, where the binding domain targets the pro-
tein to the presynaptic membrane of motor neurons.
Next, BoNT enters the neuron by receptor-mediated en-
docytosis. Once in the acidic endosome, the translocation
domain is believed to form a pore through which the light
chain is released into the cytosol of the neuron. The last
step is the LC-mediated proteolysis of specific proteins
required for neurotransmitter release.
The toxicity of BoNTs results from the metalloprotease
activity of the LC, which cleaves one of three soluble
N-ethylmaleimide-sensitive factor attachment protein re-
ceptor (SNARE) proteins required for neuroexocytosis
and release of acetylcholine. The blockade of acetylcho-
line release leads to the flaccid paralysis characteristic
of BoNT intoxication. The specific SNARE protein targeted533–542, May 2007 ª2007 Elsevier Ltd All rights reserved 533
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Inhibitors of BoNT/A ProteaseFigure 1. The Structure and Binding Sites of BoNT/A-LC
(A) Ribbon representation of the BoNT/A-LC(1–424) structure. The catalytic Zn(II) atom is shown as a metallic sphere. The four flexible active-site
loops are highlighted in cyan (50/60 loop), light blue (170 loop), orange (250 loop), and red (370 loop).
(B) The surface of the protein shown in two orientations (related by a 180 rotation in Y) with the active-site loops colored as above. In addition, the
a exosite is highlighted in green and the SNAP-25 ‘‘anchor points’’ described in [28] are colored yellow. The b exosite is comprised of residues from the
250 and 370 loops and thus, for clarity, is not highlighted with an additional color. This figure was rendered using POVScript+ [48, 49] and POVRAY
(www.povray.org).and the site of hydrolytic cleavage vary among the seven
serotypes. BoNT/A, -E, and -C1 cleave synaptosome-
associated protein of 25 kDa (SNAP-25), each at a unique
peptide bond. BoNT/C also cleaves syntaxin. BoNT/B, -D,
-F, and -G hydrolyze vesicle-associated membrane pro-
tein (VAMP; also known as synaptobrevin) [12–17]. These
metalloproteases are unique in that they possess exqui-
site substrate specificity, requiring substrates with a mini-
mum of 40 residues for efficient cleavage [18–20].
As of this writing, crystal structures have been deter-
mined for six of the seven BoNT-LC serotypes (A, B, D,
E, F, and G) [21–26]. The structures are all very similar
(1.55 A˚ root-mean-square deviation [rmsd] for Ca atoms),
as would be expected from the high sequence identity
(30%–60% among all seven serotypes) [27]. BoNT-LC
is a roughly spherical, globular protein. At the center of
the enzyme is a long a helix containing the HEXXH Zn(II)-
binding motif that marks the active-site cleft. Four flexible
loops, termed the 50/60 loop, 170 loop, 250 loop, and 370
loop (Figure 1), form the rim of the active-site cleft and pre-
sumably play a part in substrate binding. The remainder of
the protein consists of mixed a/b structure. An extended,
shallow trench runs from the active site to the opposite
face of the protein (Figure 1). There is currently only one
structure of a BoNT-SNARE protein complex [28]. The re-
cently published structure of the complex of BoNT/A with
the SNARE domain (residues 141–204) of SNAP-25 iden-
tified two exosites on the enzyme surface containing the
bulk of the enzyme-substrate contacts [29]. It is clear
that the interacting surfaces of BoNT/A and SNAP-25
are quite extensive, which would be expected to com-
plicate the search for specific inhibitors of BoNT/A-LC
metalloprotease activity.
Despite the apparent difficulties, however, a number of
small-molecule inhibitors of BoNT-LCs have been identi-534 Chemistry & Biology 14, 533–542, May 2007 ª2007 Elseviefied [30–35], though none have yet been developed into
drug therapies. Boldt et al. have recently developed
a novel class of BoNT protease inhibitors with nanomolar
affinity for the enzyme [36]. The initial lead, 4-chlorocin-
namic hydroxamate (1; Figure 2) (IC50 = 15.0 mM), was
obtained from a diverse library of hydroxamic acids.
Subsequent structure-activity relationship (SAR) studies
yielded the smallest, most potent BoNT inhibitor yet
(Ki = 300.0 nM ± 12 nM), 2,4-dichlorocinnamic hydroxa-
mate (2; Figure 2). Recently, 2 has been shown to have
in vivo efficacy, with 16% of mice dosed (at 1 mM)
surviving the BoNT challenge (5–10 times the intra-
peritoneal LD50) indefinitely with no obvious signs of
botulism [37].
In order to determine the mode of action of this novel
class of BoNT protease inhibitors, we determined the
X-ray crystal structures of a C-terminal truncation mutant
of the enzyme (residues 1–424) complexed with cinnamic
hydroxamates 1 and 2 (LC:1 and LC:2, respectively).
Because BoNT/A cleaves SNAP-25 between residues
Gln197 and Arg198, and because L-arginine hydroxa-
mate is known to be a weak inhibitor of the toxin (IC50 =
60.0 mM), we also determined the structure of the
complex of BoNT/A-LC with L-arginine hydroxamate (3;
Figure 2) bound (LC:3). Recently, Fu et al. reported the
structure of a different truncated form of BoNT/A-LC
complexed with 3 [38] in which the protein contains two
mutations (Y249F/Y250F) meant to prevent LC-catalyzed
proteolysis of the 250 loop. We report a similar LC:3
complex structure to provide a direct comparison to the
LC:1 and LC:2 complex structures. Together, these
structures provide several unexpected insights into the
binding potential of the BoNT/A-LC active site. The struc-
tures also suggest ways to improve on the already potent
inhibitor 2.r Ltd All rights reserved
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The Native BoNT/A-LC(1–424) Structure
BoNT/A-LC(1–424) crystallized in space group P21 with
two molecules in the asymmetric unit. The structure of
this truncated form of the toxin was solved by molecular re-
placement using the model of another truncated form (res-
idues 1–420; Protein Data Bank [PDB] ID code 1XTF) [28].
The truncated BoNT/A was derived from crystallization
and kinetic trials to find the construct of maximal length
that retained native activity and stability. The N-terminal
His6 tag was left intact after purification, and the sequence
intervening between the polyhistidine tag and BoNT/A-LC
(SSGLVPRGSH) is clearly visible in the electron density.
The histidine immediately prior to Met1 was designated
residue number zero. This N-terminal addition forms a por-
tion of the dimer interface observed in the nonphysiological
(crystallographic) dimer. The final model of native BoNT/A-
LC includes residues 9 to 416. Several surface loops,
including part of the 50/60 loop and the entire 250 loop,
were disordered and, thus, omitted from the model.
The unliganded structure of truncated BoNT/A light
chain (residues 1–424) was compared to the structure of
the holotoxin light chain (PDB ID code 3BTA). Least-
squares fitting in SSM [39] resulted in an rmsd for all a car-
bons common to both models of 0.92 A˚. Visual inspection
of the models shows that only the flexible loops surround-
ing the active site, two of which are disordered in the LC:1,
LC:2, and LC:3 structures (the 50/60 and 250 loops) and
the C terminus, differ significantly between the two
models (Figure 3). This indicates that the addition of the
N-terminal His6 tag and removal of the 24 C-terminal res-
idues do not impact the structure of the LC. Because it is
the full-length enzyme (residues 1–448) that would be
targeted inside neurons, we had initially attempted our
structural studies using the full-length LC (residues 1–
448). These efforts proved unsuccessful. It is worth noting
that every BoNT/A-LC structure published as of this writ-
ing uses some truncated form of the protein. Although it
is likely that the C-terminal residues may form part of the
Figure 2. Chemical Structures of the Compounds Used in
This StudyChemistry & Biology 14,active-site architecture, kinetic analysis of the full-length
and truncated forms of the LC indicates that, while there
are differences in the inhibition constants, compounds 1
and 2 are active against both forms of the metalloprotease
(R.A. Fredenburg, personal communication).
The Perfect Fit
The three enzyme-inhibitor complex structures provide
details about the interactions of the small-molecule inhib-
itors with the enzyme. As would be expected based on the
similarity of compounds 1 and 2, the inhibitors bind in al-
most identical orientations using the same set of interac-
tions. Of particular interest is the comparison between
the cinnamic hydroxamate inhibitors and L-arginine hy-
droxamate.
Both 1 and 2 bind with the cinnamyl side chain oriented
toward the 370 loop, which forms a steep wall at one end
of the active-site cleft and constitutes part of the b exosite
described by Breidenbach and Brunger [28] (Figures 4A,
4B, 5A, and 5B). Due to the predominantly hydrophobic
Figure 3. Comparison of Structures of BoNT/A-LC(1–424) and
Holotoxin LC
The backbone of BoNT/A-LC(1–424) is shown as a Ca trace colored by
the root-mean-square deviation of the Ca positions from those of the
holotoxin LC structure (PDB ID code 3BTA). The scale runs from
blue (rmsd of 0.0 A˚) to red (rmsd of 2.0 A˚). The overall rmsd value for
the entire structure is 0.92 A˚. Note that most of the structure, the active
site in particular, is blue to purple. The regions having the largest differ-
ences between the two structures (red) are almost entirely confined to
flexible loops on the surface of the protein. Two of the four active-site
loops, the 50/60 loop and the 250 loop, show large deviations between
the two structures. The catalytic Zn(II) ion (represented as a metallic
sphere) marks the position of the active site. This figure was rendered
using POVScript+ [48, 49] and POVRAY (www.povray.org).533–542, May 2007 ª2007 Elsevier Ltd All rights reserved 535
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Inhibitors of BoNT/A ProteaseFigure 4. Structures of BoNT/A-LC(1–424) Bound to Hydroxamate Inhibitors
Stereo representations of the three enzyme-inhibitor complexes ([A], LC:1; [B], LC:2; [C], LC:3) showing the unweighted 2jFoj  jFcj simulated anneal-
ing composite omit electron-density maps (green mesh) for the inhibitor and residues 366–372 (the 370 loop) contoured at 1.25s. Active-site residues
are represented as cylinders with gray carbon atoms. The inhibitors are shown in ball-and-stick representation with brass carbons. The catalytic Zn(II)
ions are rendered as metallic spheres. This figure was rendered using POVScript+ [48, 49] and POVRAY (www.povray.org).536 Chemistry & Biology 14, 533–542, May 2007 ª2007 Elsevier Ltd All rights reserved
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Inhibitors of BoNT/A ProteaseFigure 5. Schematic Representation of the Enzyme-Inhibitor Complexes
Hydrophobic interactions, metal ligands, and hydrogen bonds (distances in A˚) are depicted for the complexes of 1 (A), 2 (B), and 3 (C) with BoNT/A-
LC(1–424).nature of 1 and 2, there are very few hydrogen bonds
formed between the inhibitors and functional groups in
the enzyme active site. In both cases, the hydroxamate
moiety has displaced the zinc-liganding water molecule
observed in the native structure, and the hydroxyl oxygenChemistry & Biology 14of the hydroxamate moiety is coordinating the catalytic
Zn(II) ion. Tyr366, one of two residues thought to stabilize
the transition state during proteolysis [40], forms a hydro-
gen bond with the hydroxamate carbonyl oxygen. Glu224,
part of the HEXXH motif typical of many zinc proteases,, 533–542, May 2007 ª2007 Elsevier Ltd All rights reserved 537
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Inhibitors of BoNT/A ProteaseFigure 6. Conformational Changes in the
Active Site of BoNT/A-LC(1–424)
(A) Surface representations showing the active
sites of the LC:2 (left) and LC:3 (right) com-
plexes. In both cases, the same active site con-
forms closely to the contours of both inhibitors.
The 370 and 250 loops are colored red and or-
ange, respectively.
(B) Stereo view showing an overlay of the 370
loop from the four structures: the BoNT/A-
LC(1–424) unliganded structure (gray), LC:1
complex (light blue), LC:2 complex (dark
blue), and LC:3 complex (green). The HEXXH
Zn(II)-binding motif of the LC:2 complex and
a transparent van der Waals surface of 2 are
shown for reference. Note the dramatic rear-
rangement of residues Phe369 and Asp370.
Both figures were prepared using POVScript+
[48, 49] and POVRAY (www.povray.org).interacts with the hydroxyl oxygen of the hydroxamate.
Finally, the hydroxamate amide nitrogen interacts with
the backbone carbonyl oxygen of Phe163.
The catalytic cleft of BoNT/A-LC is unusual in that the
residues lining the site are almost entirely hydrophobic. Al-
though this observation is puzzling given the fact that this
enzyme evolved to cleave a specific Gln-Arg peptide
bond, it explains the strong preference for hydrophobic
side chains exhibited by BoNT/A-LC in high-throughput
screens [36]. The phenyl ring of the inhibitors binds in
a tight pocket formed by Ile161, Phe194, and Phe369
(Figure 5). Inhibitors 1 and 2 both completely fill the pocket
as though it were tailored to these molecules (Figure 6A).
The complementary shape of the active site explains the
results of the SAR studies on 1 [36], which showed that
substitution of the p-chloro group with a large t-butyl
group leads to a dramatic decrease in potency. Similarly,
addition of a meta-chloro group significantly reduced po-
tency. One can see from Figure 6A that any group in the
meta position would clash with the 370 loop. Conversely,
addition of the ortho-chloro substituent to 1 (compound 2)
led to a 36-fold increase in potency, as the additional
chlorine atom fills the void seen in the LC:1 structure
(Figure 6A).538 Chemistry & Biology 14, 533–542, May 2007 ª2007 ElsevierAn Equal-Opportunity Active Site
A surprising finding was made when the LC:1 and LC:2
structures were compared to the LC:3 structure. The cat-
alytic center, including the HEXXH motif, the catalytic
Zn(II) ion, and the Glu262 zinc-binding residue, is identical
across the three complex structures. The hydroxamate of
3 makes the same interactions with the enzyme described
for 1 and 2 above. However, there is a dramatic difference
in the overall shape and charge of the active site. The cat-
alytic cleft has undergone a rearrangement to bind the Arg
side chain of 3 (Figures 6A and 6B). The 370 loop takes on
a different conformation from that seen in the complexes
with the cinnamic hydroxamates. The side chain of
Phe369 is withdrawn from the catalytic cleft and in its
place is the carboxylate of Asp370, in position to partici-
pate in a salt bridge with the guanidinium group of 3.
The guanidinium group is also positioned to form a p cat-
ion bond with the face of the phenyl ring of Phe194. Finally,
the carbonyl oxygen of Ile161 is close enough (3.6 A˚) to the
guanidinium group of 3 to form a hydrogen bonding inter-
action (Figure 5C). Far from forming a rigid wall of the ac-
tive site, the 370 loop is capable of dramatic rearrange-
ments in response to the electrostatic character of the
substrate. Thus, BoNT/A-LC displays a localized form ofLtd All rights reserved
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LC LC:1 LC:2 LC:3
Resolution (A˚) (last shell)a 50.0–2.00 (2.07–2.00) 50.0–1.94 (2.01–1.94) 50.0–1.90 (1.97–1.90) 50.0–2.50 (2.59–2.50)
Wavelength (A˚) 1.0720 1.0000 1.0000 1.1000
Space group P21 P21 P21 P21
Cell dimensions (A˚) a = 73.2, b = 67.5,
c = 97.7, b = 106.5
a = 73.4, b = 67.3,
c = 98.1, b = 106.5
a = 73.8, b = 67.7,
c = 98.5, b = 106.6
a = 72.5, b = 67.2,
c = 96.9, b = 104.7
Reflections
Observed 188,216 159,950 249,622 112,375
Unique 60,496 63,852 71,771 32,735
Completeness (%)a 95.6 (79.8) 93.7 (96.3) 97.9 (95.3) 99.3 (99.6)
Rmerge (%)
a,b 7.2 (38.7) 7.4 (57.8) 9.4 (45.5) 14.3 (51.2)
I/s(I)a 11.5 (2.8) 9.0 (2.1) 12.3 (3.2) 9.2 (2.8)
Refinement Statistics
Number of protein/water
atoms per asymmetric unit
6,508/426 6,604/621 6,519/467 6,466/275
Number of reflections
(work/free)
57,400/3,078 68,126/3,626 60,589/3,232 33,688/1,778
Rwork/Rfree (%) 19.0/23.2 18.6/23.1 19.8/24.7 19.6/26.9
Average B factor (A˚2)
Protein atoms 32.3 33.8 34.3 29.0
Inhibitor na 41.1 49.8 44.4
Zn(II) ions 24.6 24.6 28.4 26.6
Water 39.2 39.5 41.3 31.5
Rms deviations
Bond lengths (A˚) 0.024 0.009 0.010 0.016
Bond angles () 1.765 1.151 1.233 1.552
na, not applicable.
a Values in parentheses apply to the high-resolution shell indicated in the resolution row.
bR = S(I  <I>)2/SI2.the induced-fit model of substrate specificity that could be
termed ‘‘substrate switching.’’
In BoNT/A, it has been suggested that Phe162, Thr192,
and Thr219 may form the S10 subsite responsible for bind-
ing the P10 arginine side chain of SNAP-25 [41]. The struc-
tures reported here as well as the structure of BoNT/A-
LC(1–420) bound to SNAP-25 [28] suggest that the S10
subsite is instead formed by residues Phe194, Ile161,
and Asp370. This interpretation is supported, at least in
part, by the recently published structure of a similar trun-
cated form of BoNT/A-LC with L-arginine hydroxamate
bound [38].
The plasticity of the BoNT/A-LC active site and the ap-
parent lack of substrate-specificity pockets other than the
S10 subsite suggest that the BoNT proteases derive their
exquisite substrate specificity almost entirely from the
a and b exosites. This concept is supported by the ability
of the LC to catalyze autoproteolytic cleavage of the 250
loop at the Tyr250-Tyr251 bond. Segelke et al. [42] ob-
served the ‘‘product complex’’ of this cleavage, whereinChemistry & Biology 14,the main chain of the cleaved 250 loop is oriented in the
opposite direction of SNAP-25 binding. Thus, the sub-
strate switching observed herein explains both the speci-
ficity for the QRATKML motif of SNAP-25 and the autopro-
teolytic activity at a hydrophobic loop.
SIGNIFICANCE
The structures of BoNT/A-LC(1–424) in complexes
with 4-chlorocinnamic hydroxamate (1) or 2,4-dichlor-
ocinnamic hydroxamate (2) provide detailed informa-
tion about the binding mode of these BoNT protease
inhibitors. Because 2 is the most potent BoNT/A-LC
inhibitor yet discovered, and has been shown to pos-
sess in vivo activity in mice prechallenged with BoNT
[37], the LC:2 structure will be valuable in the design
of more potent and selective compounds. Taken to-
gether, the three complex structures demonstrate
the remarkable plasticity of specificity of this enzyme
for small molecules. The catalytic center itself has533–542, May 2007 ª2007 Elsevier Ltd All rights reserved 539
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Inhibitors of BoNT/A Proteaselittle or no built-in selectivity for substrate residues
other than the P10 arginine. This is remarkable be-
cause the BoNT proteases are among the most spe-
cific proteases known. It would appear that BoNT/A,
if not the other BoNT serotypes, relies on the a and
b exosites for substrate specificity. The highly plastic
active site observed here, capable of accommodating
molecules of varying shape, size, and charge, may be
exploited for drug design. While it would initially seem
that this plasticity should hinder efforts to design spe-
cific inhibitors of this enzyme, the reverse may be true.
The adaptability of the BoNT/A active site could make
it possible not only to target the catalytic Zn(II) ion but
also stabilize the catalytic pocket in a conformation
that is not competent for proteolysis of SNARE com-
plex proteins.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification
The cDNA encoding the full-length (1–448) BoNT/A-LC gene was syn-
thesized by Midland Certified Reagent Company (Midland, TX). Oligo-
nucleotide primers (50-GGAATTCCATATGCCATTTGTTAATAAACAAT
TTAATT-30 and 50-CGGGATCCTTATTCAAACAATCCAGTAAAAT-30),
containing cleavage sites for the restriction endonucleases NdeI and
BamHI (underlined), were used to amplify the BoNT/A-LC(1–424)
open reading frame. The BoNT/A-LC(1–424) gene was cloned into
the pET-15b(+) vector (Stratagene, La Jolla, CA). The ligation product
(pET-15b[+]-BoNT/A-LC[1–424]) was used to transform Escherichia
coli DH5a competent cells. The purified plasmid was sequenced by
the Tufts University Core Facility.
BoNT/A-LC(1–424) was purified from E. coli BL21 (DE3)-gold cells
(Stratagene) containing the pET-15b(+)-BoNT/A-LC(1–424) plasmid
as follows. Transformed cells were grown at 30C in Luria broth con-
taining 50 mg/ml ampicillin. When the OD600 of the culture reached
0.6–1.0, the temperature was reduced to 18C, and the cultures were
induced overnight with 0.5 mM isopropyl-b-D-thiogalactopyranoside
(IPTG). Cells were harvested by centrifugation, and the pellet was sus-
pended in 100 ml of lysis buffer (20 mM HEPES [pH 8.0], 500 mM NaCl,
10 mM imidazole, 1 mM phenylmethylsulfonyl fluoride [PMSF]).
The cells were lysed using a microfluidizer, and the N-terminally
His6-tagged protein was purified by immobilized metal ion-affinity chro-
matography using HiTrap chelating resin (GE Healthcare Biosciences
AB, Uppsala, Sweden) charged with Zn(II). The protein was eluted in
20 mM HEPES (pH 8.0), 500 mM NaCl, 250 mM imidazole and was
estimated to be >95% pure by SDS-PAGE. The purified BoNT/A-
LC(1–424) was desalted by dialysis against 8 liters of 20 mM HEPES
(pH 7.5), 50 mM NaCl. Finally, the purified, desalted enzyme was con-
centrated to 10 mg/ml using Amicon centrifugal concentrators (Milli-
pore, Billerica, MA) having a nominal molecular weight cutoff of 10 kDa.
Crystallization and Data Collection
Crystals of the unliganded, truncated BoNT/A-LC were obtained by the
hanging drop vapor diffusion method. Drops were formed of equal
parts BoNT/A-LC(1–424) at 10 mg/ml in 20 mM HEPES (pH 7.5),
50 mM NaCl and well solution containing 10%–15% polyethylene gly-
col monomethyl ether 2000 (PEG-2K MMe), 0.3 M (NH4)2HPO4, 50 mM
Tris (pH 8.5). Compound 2 was cocrystallized with the enzyme by
adding 500 mM 2 to the protein solution. Small (0.13 0.023 <0.01 mm),
plate-like crystals grew in 1–3 days. Larger crystals were obtained by
microseeding.
X-ray diffraction data were collected at the National Synchrotron
Light Source, beamline X12B. The LC:1 structure was obtained
by soaking crystals of the unliganded enzyme for 7 min in a solution
of 20% PEG-2K MMe, 0.3 M (NH4)2HPO4, 50 mM Tris (pH 8.5), 20%540 Chemistry & Biology 14, 533–542, May 2007 ª2007 Elsevierglycerol, and 5 mM 1. The soaked crystal (0.4 3 0.05 3 0.01 mm)
was flash-cooled to 100K in a gaseous N2 stream and data were
collected to 1.90 A˚. For the LC:2 complex, data were collected
from a BoNT/A-LC(1–424) cocrystal (vide supra). The 0.5 3 0.1 3
0.02 mm crystal was transferred in three steps (5%, 10%, and
20% glycerol) to a solution of 20% PEG-2K MMe, 0.3 M (NH4)2HPO4,
50 mM Tris (pH 8.5), 20% glycerol and flash-cooled to 100K. The com-
plex of the enzyme with L-arginine hydroxamate was obtained by
soaking a 0.4 3 0.1 3 0.01 mm crystal of the unliganded enzyme
for 60 hr in 20% PEG-2K MMe, 0.3 M (NH4)2HPO4, 50 mM Tris
(pH 8.5), 20% glycerol, and 50 mM 3. Data were collected at 100K.
Finally, data were collected on a crystal of the unliganded enzyme
for comparison to the three enzyme-inhibitor complexes. All four
data sets were indexed and scaled using DENZO and SCALEPACK
[43]. Data collection statistics for all four data sets can be found in
Table 1.
Structure Determination and Model Refinement
The structure of the unliganded BoNT/A-LC(1–424) was solved by mo-
lecular replacement using the structure of a mutant form of BoNT/A-LC
containing residues 1–420 (PDB ID code 1XTF) as the search model.
Repeating the molecular replacement using other BoNT/A-LC struc-
tures (PDB ID codes 1E1H and 3BTA) resulted in a nearly identical
model of BoNT/A-LC(1–424) after several rounds of refinement (data
not shown). Molecular replacement was performed with PHASER
[44]. The three enzyme-inhibitor complex structures were each phased
by difference Fourier methods using phases from the unliganded
BoNT/A-LC(1–424) model.
All four models were refined using REFMAC5 [45]. The same general
refinement protocol was used for all four models. Briefly, after one
round of rigid body refinement, individual atomic coordinates and iso-
tropic temperature factors were refined. Next, water molecules visible
as spherical peaks in jFoj  jFcj electron-density maps contoured at
3.0s were added to the models. Missing sections of the model were
built by an iterative process of model building in Coot [46] and refine-
ment in REFMAC5. Once the R factors converged, the inhibitor mole-
cules were built into jFoj  jFcj electron density. No noncrystallo-
graphic symmetry restraints were used because they did not
improve the phases significantly. The models were finished by making
changes suggested by validation tools in Coot and MOLPROBITY [47].
Refinement statistics for the four models are given in Table 1.
ACKNOWLEDGMENTS
This work was supported by contract NO1-AI30050 from the National
Institutes of Health (NIH) and the National Institute of Allergy and Infec-
tious Diseases (NIAID) as well as NIH training grant HL07291 (to
N.R.S.).
Received: October 5, 2006
Revised: February 7, 2007
Accepted: March 14, 2007
Published: May 29, 2007
REFERENCES
1. Hanson, D. (2004). Botulinum toxin: a bioterrorism weapon.
Emerg. Med. Serv. 33, 55–59.
2. Josko, D. (2004). Botulin toxin: a weapon in terrorism. Clin. Lab.
Sci. 17, 30–34.
3. Patocka, J., Splino, M., and Merka, V. (2005). Botulism and bioter-
rorism: how serious is this problem? Acta Medica (Hradec Kralove)
48, 23–28.
4. Wein, L.M., and Liu, Y. (2005). Analyzing a bioterror attack on the
food supply: the case of botulinum toxin in milk. Proc. Natl. Acad.
Sci. USA 102, 9984–9989.Ltd All rights reserved
Chemistry & Biology
Inhibitors of BoNT/A Protease5. Montecucco, C., and Schiavo, G. (1995). Structure and function of
tetanus and botulinum neurotoxins. Q. Rev. Biophys. 28, 423–472.
6. Krieglstein, K.G., DasGupta, B.R., and Henschen, A.H. (1994).
Covalent structure of botulinum neurotoxin type A: location of
sulfhydryl groups, and disulfide bridges and identification of C-
termini of light and heavy chains. J. Protein Chem. 13, 49–57.
7. Sagane, Y., Watanabe, T., Kouguchi, H., Sunagawa, H., Inoue, K.,
Fujinaga, Y., Oguma, K., and Ohyama, T. (1999). Dichain structure
of botulinum neurotoxin: identification of cleavage sites in types C,
D, and F neurotoxin molecules. J. Protein Chem. 18, 885–892.
8. Finkelstein, A. (1990). Channels formed in phospholipid bilayer
membranes by diphtheria, tetanus, botulinum and anthrax toxin.
J. Physiol. (Paris) 84, 188–190.
9. Hambleton, P. (1994). Botulinum toxin: structure and pharmacol-
ogy. Eur. Arch. Otorhinolaryngol. (Suppl ), S200–S202.
10. Montecucco, C., and Schiavo, G. (1994). Mechanism of action of
tetanus and botulinum neurotoxins. Mol. Microbiol. 13, 1–8.
11. Montecucco, C., Schiavo, G., and Rossetto, O. (1996). The mech-
anism of action of tetanus and botulinum neurotoxins. Arch. Tox-
icol. Suppl. 18, 342–354.
12. Yamasaki, S., Binz, T., Hayashi, T., Szabo, E., Yamasaki, N.,
Eklund, M., Jahn, R., and Niemann, H. (1994). Botulinum neuro-
toxin type G proteolyses the Ala81-Ala82 bond of rat synaptobre-
vin 2. Biochem. Biophys. Res. Commun. 200, 829–835.
13. Yamasaki, S., Hu, Y., Binz, T., Kalkuhl, A., Kurazono, H., Tamura,
T., Jahn, R., Kandel, E., and Niemann, H. (1994). Synaptobrevin/
vesicle-associated membrane protein (VAMP) of Aplysia californ-
ica: structure and proteolysis by tetanus toxin and botulinal neuro-
toxins type D and F. Proc. Natl. Acad. Sci. USA 91, 4688–4692.
14. Schiavo, G., Benfenati, F., Poulain, B., Rossetto, O., Polverino de
Laureto, P., DasGupta, B.R., and Montecucco, C. (1992). Tetanus
and botulinum-B neurotoxins block neurotransmitter release by
proteolytic cleavage of synaptobrevin. Nature 359, 832–835.
15. Binz, T., Blasi, J., Yamasaki, S., Baumeister, A., Link, E., Sudhof,
T.C., Jahn, R., and Niemann, H. (1994). Proteolysis of SNAP-25
by types E and A botulinal neurotoxins. J. Biol. Chem. 269,
1617–1620.
16. Blasi, J., Chapman, E.R., Yamasaki, S., Binz, T., Niemann, H., and
Jahn, R. (1993). Botulinum neurotoxin C1 blocks neurotransmitter
release by means of cleaving HPC-1/syntaxin. EMBO J. 12, 4821–
4828.
17. Blasi, J., Chapman, E.R., Link, E., Binz, T., Yamasaki, S., De Ca-
milli, P., Sudhof, T.C., Niemann, H., and Jahn, R. (1993). Botulinum
neurotoxin A selectively cleaves the synaptic protein SNAP-25.
Nature 365, 160–163.
18. Washbourne, P., Pellizzari, R., Baldini, G., Wilson, M.C., and Mon-
tecucco, C. (1997). Botulinum neurotoxin types A and E require the
SNARE motif in SNAP-25 for proteolysis. FEBS Lett. 418, 1–5.
19. Schmidt, J.J., and Bostian, K.A. (1995). Proteolysis of synthetic
peptides by type A botulinum neurotoxin. J. Protein Chem. 14,
703–708.
20. Yamasaki, S., Baumeister, A., Binz, T., Blasi, J., Link, E., Cornille,
F., Roques, B., Fykse, E.M., Sudhof, T.C., Jahn, R., et al. (1994).
Cleavage of members of the synaptobrevin/VAMP family by types
D and F botulinal neurotoxins and tetanus toxin. J. Biol. Chem.
269, 12764–12772.
21. Arndt, J.W., Chai, Q., Christian, T., and Stevens, R.C. (2006).
Structure of botulinum neurotoxin type D light chain at 1.65 A˚
resolution: repercussions for VAMP-2 substrate specificity. Bio-
chemistry 45, 3255–3262.
22. Arndt, J.W., Yu, W., Bi, F., and Stevens, R.C. (2005). Crystal
structure of botulinum neurotoxin type G light chain: serotype di-
vergence in substrate recognition. Biochemistry 44, 9574–9580.Chemistry & Biology 14,23. Agarwal, R., Eswaramoorthy, S., Kumaran, D., Binz, T., and Swa-
minathan, S. (2004). Structural analysis of botulinum neurotoxin
type E catalytic domain and its mutant Glu212/Gln reveals the
pivotal role of the Glu212 carboxylate in the catalytic pathway. Bio-
chemistry 43, 6637–6644.
24. Swaminathan, S., and Eswaramoorthy, S. (2000). Structural
analysis of the catalytic and binding sites of Clostridium botulinum
neurotoxin B. Nat. Struct. Biol. 7, 693–699.
25. Lacy, D.B., Tepp, W., Cohen, A.C., DasGupta, B.R., and Stevens,
R.C. (1998). Crystal structure of botulinum neurotoxin type A and
implications for toxicity. Nat. Struct. Biol. 5, 898–902.
26. Agarwal, R., Binz, T., and Swaminathan, S. (2005). Structural anal-
ysis of botulinum neurotoxin serotype F light chain: implications on
substrate binding and inhibitor design. Biochemistry 44, 11758–
11765.
27. Lacy, D.B., and Stevens, R.C. (1999). Sequence homology and
structural analysis of the clostridial neurotoxins. J. Mol. Biol.
291, 1091–1104.
28. Breidenbach, M.A., and Brunger, A.T. (2004). Substrate recogni-
tion strategy for botulinum neurotoxin serotype A. Nature 432,
925–929.
29. Breidenbach, M.A., and Brunger, A.T. (2005). New insights into
clostridial neurotoxin-SNARE interactions. Trends Mol. Med. 11,
377–381.
30. Anne, C., Turcaud, S., Quancard, J., Teffo, F., Meudal, H., Fournie-
Zaluski, M.C., and Roques, B.P. (2003). Development of potent in-
hibitors of botulinum neurotoxin type B. J. Med. Chem. 46, 4648–
4656.
31. Blommaert, A., Turcaud, S., Anne, C., and Roques, B.P. (2004).
Small tripeptide surrogates with low nanomolar affinity as potent
inhibitors of the botulinum neurotoxin B metallo-proteolytic activ-
ity. Bioorg. Med. Chem. 12, 3055–3062.
32. Burnett, J.C., Schmidt, J.J., Stafford, R.G., Panchal, R.G.,
Nguyen, T.L., Hermone, A.R., Vennerstrom, J.L., McGrath, C.F.,
Lane, D.J., Sausville, E.A., et al. (2003). Novel small molecule
inhibitors of botulinum neurotoxin A metalloprotease activity. Bio-
chem. Biophys. Res. Commun. 310, 84–93.
33. Schmidt, J.J., and Stafford, R.G. (2002). A high-affinity competitive
inhibitor of type A botulinum neurotoxin protease activity. FEBS
Lett. 532, 423–426.
34. Schmidt, J.J., and Stafford, R.G. (2005). Botulinum neurotoxin se-
rotype F: identification of substrate recognition requirements and
development of inhibitors with low nanomolar affinity. Biochemis-
try 44, 4067–4073.
35. Park, J.G., Sill, P.C., Makiyi, E.F., Garcia-Sosa, A.T., Millard, C.B.,
Schmidt, J.J., and Pang, Y.P. (2006). Serotype-selective, small-
molecule inhibitors of the zinc endopeptidase of botulinum neuro-
toxin serotype A. Bioorg. Med. Chem. 14, 395–408.
36. Boldt, G.E., Kennedy, J.P., and Janda, K.D. (2006). Identification
of a potent botulinum neurotoxin A protease inhibitor using in situ
lead identification chemistry. Org. Lett. 8, 1729–1732.
37. Eubanks, L.M., Hixon, M.S., Jin, W., Hong, S., Clancy, C.M., Tepp,
W.H., Baldwin, M.R., Malizio, C.J., Goodnough, M.C., Barbieri,
J.T., et al. (2007). An in vitro and in vivo disconnect uncovered
through high-throughput identification of botulinum neurotoxin A
antagonists. Proc. Natl. Acad. Sci. USA 104, 2602–2607.
38. Fu, Z., Chen, S., Baldwin, M.R., Boldt, G.E., Crawford, A., Janda,
K.D., Barbieri, J.T., and Kim, J.J. (2006). Light chain of botulinum
neurotoxin serotype A: structural resolution of a catalytic interme-
diate. Biochemistry 45, 8903–8911.
39. Krissinel, E., and Henrick, K. (2004). Secondary-structure match-
ing (SSM), a new tool for fast protein structure alignment in three
dimensions. Acta Crystallogr. D Biol. Crystallogr. 60, 2256–2268.533–542, May 2007 ª2007 Elsevier Ltd All rights reserved 541
Chemistry & Biology
Inhibitors of BoNT/A Protease40. Binz, T., Bade, S., Rummel, A., Kollewe, A., and Alves, J. (2002).
Arg(362) and Tyr(365) of the botulinum neurotoxin type A light
chain are involved in transition state stabilization. Biochemistry
41, 1717–1723.
41. Agarwal, R., Binz, T., and Swaminathan, S. (2005). Analysis of
active site residues of botulinum neurotoxin E by mutational,
functional, and structural studies: Glu335Gln is an apoenzyme.
Biochemistry 44, 8291–8302.
42. Segelke, B., Knapp, M., Kadkhodayan, S., Balhorn, R., and Rupp,
B. (2004). Crystal structure of Clostridium botulinum neurotoxin
protease in a product-bound state: evidence for noncanonical
zinc protease activity. Proc. Natl. Acad. Sci. USA 101, 6888–6893.
43. Otwinowski, Z., and Minor, W. (1997). Processing of X-ray diffrac-
tion data collected in oscillation mode. Methods Enzymol. 276,
307–326.
44. CCP4 (Collaborative Computational Project, Number 4) (1994).
The CCP4 suite: programs for protein crystallography. Acta Crys-
tallogr. D Biol. Crystallogr. 50, 760–763.
45. Murshudov, G.N., Vagin, A.A., and Dodson, E.J. (1997). Refine-
ment of macromolecular structures by the maximum-likelihood
method. Acta Crystallogr. D Biol. Crystallogr. 53, 240–255.542 Chemistry & Biology 14, 533–542, May 2007 ª2007 Elsevie46. Emsley, P., and Cowtan, K. (2004). Coot: model-building tools for
molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–
2132.
47. Davis, I.W., Murray, L.W., Richardson, J.S., and Richardson, D.C.
(2004). MOLPROBITY: structure validation and all-atom contact
analysis for nucleic acids and their complexes. Nucleic Acids
Res. 32, W615–W619.
48. Kraulis, P. (1991). MOLSCRIPT: a program to produce both de-
tailed and schematic plots of protein structures. J. Appl. Cryst.
24, 946–950.
49. Fenn, T.D., Ringe, D., and Petsko, G.A. (2003). POVScript+: a pro-
gram for model and data visualization using persistence of vision
ray-tracing. J. Appl. Cryst. 36, 944–947.
Accession Numbers
Coordinates and structure factors for C. botulinum neurotoxin sero-
type A light chain in the unliganded form and bound to 4-chlorocin-
namic hydroxamate, 2,4-dichlorocinnamic hydroxamate, and L-argi-
nine hydroxamate have been deposited in the Protein Data Bank
under ID codes 2IMC, 2ILP, 2IMA, and 2IMB, respectively.r Ltd All rights reserved
